Pyxis Oncology (PYXS) Competitors $1.34 +0.02 (+1.52%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.02 (+1.49%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. DSGN, RNAC, DRUG, NGNE, HUMA, PBYI, ACB, GLUE, FHTX, and AVIRShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), Puma Biotechnology (PBYI), Aurora Cannabis (ACB), Monte Rosa Therapeutics (GLUE), Foghorn Therapeutics (FHTX), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Design Therapeutics Cartesian Therapeutics Bright Minds Biosciences Neurogene Humacyte Puma Biotechnology Aurora Cannabis Monte Rosa Therapeutics Foghorn Therapeutics Atea Pharmaceuticals Pyxis Oncology (NASDAQ:PYXS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Do institutionals & insiders hold more shares of PYXS or DSGN? 39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 23.5% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, PYXS or DSGN? Design Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Design Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M5.15-$77.33M-$1.60-0.84Design TherapeuticsN/AN/A-$49.59M-$1.12-4.70 Do analysts rate PYXS or DSGN? Pyxis Oncology presently has a consensus price target of $8.67, suggesting a potential upside of 546.77%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer PYXS or DSGN? In the previous week, Pyxis Oncology had 17 more articles in the media than Design Therapeutics. MarketBeat recorded 22 mentions for Pyxis Oncology and 5 mentions for Design Therapeutics. Pyxis Oncology's average media sentiment score of 1.01 beat Design Therapeutics' score of -0.43 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, PYXS or DSGN? Pyxis Oncology has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Is PYXS or DSGN more profitable? Design Therapeutics' return on equity of -27.15% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -68.56% -52.14% Design Therapeutics N/A -27.15%-26.07% SummaryPyxis Oncology and Design Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.86M$2.51B$5.76B$9.59BDividend YieldN/A1.67%4.41%4.09%P/E Ratio-0.8422.6131.1026.05Price / Sales5.15747.15470.24120.75Price / CashN/A180.4637.7358.48Price / Book0.955.939.536.61Net Income-$77.33M$31.83M$3.26B$265.56M7 Day Performance8.94%1.80%2.11%1.98%1 Month Performance18.58%4.36%5.12%1.33%1 Year Performance-63.29%11.44%31.25%21.15% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.387 of 5 stars$1.34+1.5%$8.67+546.8%-63.6%$81.86M$16.15M-0.8460Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeDSGNDesign Therapeutics0.1677 of 5 stars$5.40+1.3%N/A-1.9%$303.53MN/A-4.8240RNACCartesian Therapeutics2.5621 of 5 stars$11.28-0.4%$40.00+254.6%-26.3%$294.60M$38.91M-0.2164Positive NewsGap UpDRUGBright Minds Biosciences2.723 of 5 stars$45.55+8.9%$83.25+82.8%+3,990.3%$294.58MN/A-48.98N/ATrending NewsAnalyst ForecastAnalyst RevisionNGNENeurogene1.7612 of 5 stars$20.45-0.3%$46.17+125.8%-44.9%$292.72M$930K-4.7490HUMAHumacyte2.4187 of 5 stars$1.80-4.3%$10.64+491.3%-76.2%$291.62M$1.57M-4.00150Insider TradePBYIPuma Biotechnology4.2061 of 5 stars$5.01-12.6%$7.00+39.7%+93.3%$288.63M$238.06M5.11200High Trading VolumeACBAurora Cannabis0.8458 of 5 stars$5.12+0.8%N/A-25.2%$286.79M$246.72M-26.951,130GLUEMonte Rosa Therapeutics2.1155 of 5 stars$4.56-0.4%$15.33+236.3%-31.1%$282.86M$75.62M12.6790FHTXFoghorn Therapeutics2.3632 of 5 stars$5.10+2.4%$12.00+135.3%-31.9%$281.52M$22.60M-4.29120AVIRAtea Pharmaceuticals1.7908 of 5 stars$3.53+0.9%$6.00+70.0%-7.6%$277.75MN/A-2.1970 Related Companies and Tools Related Companies DSGN Alternatives RNAC Alternatives DRUG Alternatives NGNE Alternatives HUMA Alternatives PBYI Alternatives ACB Alternatives GLUE Alternatives FHTX Alternatives AVIR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access